DOI: 10.12890/2024_004316
Eosinophilic gastroenteritis following COVID-19 mRNA vaccination
Authors
yy_yopi@yahoo.co.jp
Abstract
Introduction: Large-scale clinical studies for COVID-19 vaccines have shown the infection-preventing effect and short-term adverse effects. Some rare illnesses such as eosinophilia can develop following COVID-19 vaccinations.
Case description: We report a case of 65-year-old man with unexplained abdominal pain that developed 2 weeks after COVID-19 mRNA vaccination. The patient had received a second dose of COVID-19 mRNA vaccine and revealed eosinophilia at the first visit to our hospital. Eosinophil infiltration was observed in the lamina propria of the duodenum by a step biopsy. Montelukast 10 mg was administered as the initial treatment of eosinophilic gastroenteritis (EGE), and the abdominal pain was improved.
Discussion: The strong influence of COVID-19 vaccination on the development of EGE remains unproven. Reports of eosinophilia following COVID-19 vaccination have discussed that COVID-19 mRNA vaccination triggered an eosinophilic response.
Conclusion: This case presented EGE that developed following COVID-19 mRNA vaccination, which would be a rare adverse event.
References
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603–2615.
- Molnár A, Studinger P, Ledó N. Diagnostic and therapeutic approach in ANCA-associated glomerulonephritis: a review on management strategies. Front Med (Lausanne) 2022;9:884188.
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
- Ishizuka K, Katayama K, Kaji Y, Tawara J, Ohira Y. Non-episodic angioedema with eosinophilia after BNT162b2 mRNA COVID-19 vaccination. QJM 2021;114:745–746.
- Lee JY, Lee JH. mRNA COVID-19 vaccine-associated subserosal eosinophilic gastroenteritis: a case report. J Korean Med Sci 2022;37:e233.
- Nune A, Durkowski V, Pillay SS, Barman B, Elwell H, Bora K, et al. New-onset rheumatic immune-mediated inflammatory diseases following SARS-CoV-2 vaccinations until May 2023: a systematic review. Vaccines (Basel) 2023;11:1571.
